Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Amifampridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KDM6B | O15054 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | AOC1 | P19801 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amifampridine SCHEMBL3958357 | 0.90 | ALDH1A1 (0.50) | KDM4EALDH1A1TDP1MEN1KDM6B | |
| Amifampridine SCHEMBL22494082 | 0.90 | ALDH1A1 (0.50) | KDM4EALDH1A1TDP1MEN1KDM6B | |
| Amifampridine SCHEMBL29354458 | 0.80 | — | — | |
| Amifampridine SCHEMBL21273 | 0.80 | — | — | |
| Amifampridine SCHEMBL27516080 | 0.78 | GAA (0.52) | KDM4EALDH1A1TDP1MEN1KDM6B | |
| Amifampridine SCHEMBL8907368 | 0.78 | GAA (0.56) | KDM4EALDH1A1TDP1MEN1KDM6B | |
| Amifampridine SCHEMBL19410631 | 0.78 | GAA (0.56) | KDM4EALDH1A1TDP1MEN1KDM6B | |
| Amifampridine SCHEMBL30609183 | 0.78 | — | — | |
| Amifampridine SCHEMBL11016903 | 0.78 | — | — | |
| Amifampridine SCHEMBL28271256 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082688-A1 | COMPOSITIONS AND METHODS FOR WILLIAMS SYNDROME (WS) THERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-03-13 | — | — | US | disclosed |
| US-20240082312-A1 | COMPOSITIONS AND METHODS FOR WILLIAMS SYNDROME (WS) THERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-03-14 | — | — | US | disclosed |
| US-11730769-B2 | Compositions and methods for Williams Syndrome (WS) therapy | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| EP-3727587-A1 | COMPOSITIONS AND METHODS FOR WILLIAMS SYNDROME (WS) THERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200316132-A1 | COMPOSITIONS AND METHODS FOR WILLIAMS SYNDROME (WS) THERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730769-B2 | Compositions and methods for Williams Syndrome (WS) therapy | MAG, PMP22, WDR77 | KDM4E 3566/4885ALDH1A1 4430/4885TDP1 1318/4885 |
| US-20250082688-A1 | COMPOSITIONS AND METHODS FOR WILLIAMS SYNDROME (WS) THERAPY | MAG, PMP22, WDR77 | KDM4E 3544/4885ALDH1A1 4440/4885TDP1 1313/4885 |
| US-20200316132-A1 | COMPOSITIONS AND METHODS FOR WILLIAMS SYNDROME (WS) THERAPY | MAG, PMP22, WDR77 | KDM4E 3566/4885ALDH1A1 4430/4885TDP1 1318/4885 |
| US-20240082312-A1 | COMPOSITIONS AND METHODS FOR WILLIAMS SYNDROME (WS) THERAPY | MAG, PMP22, WDR77 | KDM4E 3566/4885ALDH1A1 4430/4885TDP1 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.